Friday, October 27, 2023
12:00PM – 1:00PM ET
Please note this virtual program is 12:00PM Eastern, 11:00AM Central, 10:00AM Mountain and 9:00AM Pacific.
 FACULTY
 |
Ronan Kelly, MD Director of the Charles A. Sammons Cancer Center Baylor University Medical Center Dallas, TX |
PROGRAM OVERVIEW
The proposed virtual series and online enduring educational activity is designed to meet the educational needs of Department of Veterans Affairs clinicians including medical oncologists, oncology nurses, pharmacists, nurse practitioners and other members of the multidisciplinary team to maintain an up-to-date understanding of the latest data on HER2-directed antibody-drug conjugate therapy in the management of patients with advanced gastric and esophageal junction cancer. The education will seek to increase clinicians’ ability to: understand HER2-low levels of expression in patients with gastrointestinal cancer; evaluate clinical trials data for treating patients with advanced HER2 gastrointestinal cancer and apply that to potential treatment options for patients with HER2-low gastrointestinal cancer; and recognize the signs and symptoms of ADC adverse events and apply this knowledge to the management of ADC-related adverse events in patients with HER2-low gastrointestinal cancer.
TARGET AUDIENCE
This activity is designed to meet the educational needs of Department of Veterans Affairs clinicians, including medical oncologists, oncology nurses, pharmacists, nurse practitioners, and other members of the multidisciplinary team to maintain an up-to-date understanding of the latest data on HER2 directed antibody-drug conjugate therapy in the management of patients with advanced gastric and esophageal junction cancer.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Discuss HER2 levels of expression and their application in the treatment of patients with either gastric or esophageal junction cancer
- Apply new clinical trials data to the management of Veterans with HER2 gastroesophageal junction cancer
- Describe the presentation and management of adverse events associated with antibody-drug conjugate, HER2-targeted therapy in advanced or metastatic gastrointestinal cancer
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtually live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES (ANCC) CREDIT DESIGNATION
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
